Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
CAN-3110 by Candel Therapeutics for Anaplastic Astrocytoma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...
Aglatimagene besadenovec by Candel Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...
CAN-3110 by Candel Therapeutics for Oligodendroglioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase I...
CAN-3110 by Candel Therapeutics for Recurrent Malignant Glioma: Likelihood of Approval
CAN-3110 is under clinical development by Candel Therapeutics and currently in Phase I for Recurrent Malignant Glioma. According to GlobalData,...
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...